Global Recombinant Protein Biopharmaceuticals Market Growth (Status and Outlook) 2025-2031

According to this study, the global Recombinant Protein Biopharmaceuticals market size will reach US$ 311339 million by 2031.

Recombinant protein biopharmaceuticals are therapeutic proteins produced through recombinant DNA technology, in which genes encoding the desired protein are inserted into host cells (such as bacteria, yeast, or mammalian cells) for expression and large-scale production. These biologic drugs mimic or enhance natural proteins in the human body and are widely used in treating cancers, autoimmune diseases, metabolic disorders, and infectious diseases.

United States market for Recombinant Protein Biopharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Recombinant Protein Biopharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Recombinant Protein Biopharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Recombinant Protein Biopharmaceuticals players cover Novo Nordisk, Amgen, Eli Lilly, Sanofi, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Recombinant Protein Biopharmaceuticals Industry Forecast” looks at past sales and reviews total world Recombinant Protein Biopharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Protein Biopharmaceuticals sales for 2025 through 2031. With Recombinant Protein Biopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Protein Biopharmaceuticals industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Protein Biopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant Protein Biopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Protein Biopharmaceuticals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Protein Biopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Protein Biopharmaceuticals.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Protein Biopharmaceuticals market by product type, application, key players and key regions and countries.

Segmentation by Type:
Fusion Protein
Recombinant Growth Factor
Recombinant Hormone
Recombinant Interferon
Recombinant Interleukin
Recombinant Coagulation Factor
Other

Segmentation by Application:
Cancers
Autoimmune Diseases
Metabolic Disorders
Infectious Diseases

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Amgen
Eli Lilly
Sanofi
Bayer
Bristol-Myers Squibb
GlaxoSmithKline
AbbVie
Sandoz
Biogen
Pfizer
GenSci
3SBIO
Organon Pharma
Roche
Swedish Orphan Biovitrum
CSPC
Johnson & Johnson
Merck
Takeda

Please note: The report will take approximately 2 business days to prepare and deliver.